RenovoRx (NASDAQ:RNXT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of RenovoRx (NASDAQ:RNXT) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Other equities analysts have also recently issued reports about the stock. Ascendiant Capital Markets upped their target price on shares of RenovoRx from $12.00 to $12.50 and gave the company a “buy” rating in a research note on Friday, November 21st. Jones Trading raised shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of RenovoRx in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, RenovoRx has an average rating of “Moderate Buy” and an average target price of $7.75.

RenovoRx Stock Up 0.3%

Shares of RNXT stock opened at $0.93 on Friday. RenovoRx has a 12 month low of $0.70 and a 12 month high of $1.45. The firm has a market cap of $34.21 million, a PE ratio of -2.59 and a beta of 1.31. The stock has a 50 day moving average of $0.96 and a 200-day moving average of $1.04.

Institutional Trading of RenovoRx

Several institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares in the last quarter. Bleichroeder LP grew its stake in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after purchasing an additional 61,379 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of RenovoRx in the 2nd quarter valued at approximately $98,000. Citadel Advisors LLC acquired a new position in shares of RenovoRx in the 3rd quarter worth approximately $154,000. Finally, AIGH Capital Management LLC lifted its position in shares of RenovoRx by 8.4% during the 4th quarter. AIGH Capital Management LLC now owns 2,833,894 shares of the company’s stock worth $2,380,000 after buying an additional 218,701 shares during the period. 3.10% of the stock is currently owned by institutional investors and hedge funds.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.